Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology, based on its proprietary technological platform DOS47, announces the appointment of Dr. Thomas Mehrling MD, PhD as Medical Adviser.
Dr. Mehrling is a medical oncologist with extensive experience in clinical trials and drug development, having worked with several Big Pharma companies in the past with a focus on oncology-related assets.